Keros Therapeutics (NASDAQ:KROS) Shares Down 8.9% – What’s Next?

Keros Therapeutics, Inc. (NASDAQ:KROS) shares dropped 8.9% during mid-day trading on Monday . The stock traded as low as $13.07 and last traded at $13.26. Approximately 220,614 shares traded hands during trading, a decline of 72% from the average daily volume of 795,165 shares. The stock had previously closed at $14.56.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KROS. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating for the company. Scotiabank dropped their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research note on Friday, December 13th. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. HC Wainwright dropped their price target on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

Keros Therapeutics Trading Down 2.7 %

The stock has a 50 day moving average of $39.77 and a 200-day moving average of $47.88. The stock has a market capitalization of $505.53 million, a P/E ratio of -2.40 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.33) EPS. Research analysts anticipate that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the period. KBC Group NV increased its position in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its position in Keros Therapeutics by 36.7% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after buying an additional 1,033 shares in the last quarter. Arizona State Retirement System raised its position in shares of Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Algert Global LLC raised its holdings in shares of Keros Therapeutics by 10.6% in the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock worth $717,000 after buying an additional 1,505 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.